Junichi Tomomatsu

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Shunji Takahashi, Yutaka Fujiwara, Kenji Nakano et al. · Cancer Science · 2021 · 72 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma

Akihiro Ohmoto, Yukiko Sato, Reimi Asaka et al. · Modern Pathology · 2021 · 40 citations · Full text

Medicine, Oncology, Cancer Genetics +15

Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib

Naoki Fukuda, Xiaofei Wang, Akihiro Ohmoto et al. · In Vivo · 2020 · 33 citations · Full text

Medicine, Oncology, Pharmacology +14

Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib

Naoki Fukuda, Kazuhisa Toda, Yu Fujiwara et al. · In Vivo · 2020 · 31 citations · Full text

Medicine, Oncology, Pharmacology +16

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors

Noboru Yamamoto, Toshio Shimizu, Kan Yonemori et al. · Investigational New Drugs · 2021 · 31 citations · Full text

Pharmacy, Oncology, Pharmacology +13